M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

M&As this week: Northsight Capital, GL Capital and ABG Management, Tonghua Golden Horse Pharmaceutical Industry

17 Nov 2016

Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis industry.

Northsight Capital plans to acquire Stargreen Holdings to expand its business and presence in the cannabis industry.

Based on the purchase consideration, Northsight expects the acquisition to cost between $5m and $20m.

"Based on the purchase consideration, Northsight expects the acquisition to cost between $5m and $20m."

The company will issue 210 million of its common stock shares to raise funds for the acquisition.

GL Capital Management and ABG Management plan to acquire SciClone Pharma for a purchase consideration of $570m.

The companies plan to fund the acquisition through debt and equity financing.

Morgan Stanley is acting as transaction adviser, and Skadden Arps, Slate Meagher &Flom and Fangda Law Firm are acting as legal advisers for the acquisition.

Tonghua Golden Horse Pharmaceutical Industry plans to acquire medicinal materials firm Lhasa.

The company expects the acquisition to cost up to $1.6m.